New insight into the management of IgA nephropathy
- 91 Downloads
To the Editor
IgA nephropathy (IgAN) is the most common glomerulonephritis in the world, especially in the Asian population. Jicheng Lv and his colleagues have shed new light on the management of IgAN in this issue of JAMA . In the previous study, the IgAN patients with GFR < 50 mL/min were almost excluded from trials. The range of eGFR was 60–90 mL/min/1.73 m2 with glucocorticoid monotherapy in the STOP-IgAN study . However, the wide range of inclusion criteria of eGFR (20–120 mL/min/1.73 m2)  is of great advantage in the design, and results indicated that proteinuria had been improved significantly even during the stage of eGFR 20–50 mL/min/1.73 m2. International research suggests that the lower the eGFR, the greater the risk of adverse events , so the possible risk of serious side effects of corticosteroids might be lower if the low limit of eGFR is up to 30 or more than 40 mL/min/1.73 m2. In the TESTING trials, an almost threefold lower risk for kidney failure, opposed...
This work was supported by grants from Chinese Society of Nephrology (14050430580).
Compliance with ethical standards
Conflict of interest
No potential conflict of interest relevant to this letter was reported.
- 3.Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013; 3(Suppl):1–150.Google Scholar